Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes
Open Access
- 11 November 2009
- journal article
- research article
- Published by Springer Nature in Retrovirology
- Vol. 6 (1), 103
- https://doi.org/10.1186/1742-4690-6-103
Abstract
Background: Integrase inhibitors are currently being incorporated into highly active antiretroviral therapy (HAART). Due to high HIV variability, integrase inhibitor efficacy must be evaluated against a range of integrase enzymes from different subtypes. Methods: This study compares the enzymatic activities of HIV-1 integrase from subtypes B and C as well as susceptibility to various integrase inhibitors in vitro. The catalytic activities of both enzymes were analyzed in regard to each of 3' processing and strand transfer activities both in the presence and absence of the integrase inhibitors raltegravir (RAL), elvitegravir (EVG), and MK-2048. Results: Our results show that integrase function is similar with enzymes of either subtype and that the various integrase strand transfer inhibitors (INSTIs) that were employed possessed similar inhibitory activity against both enzymes. Conclusion: This suggests that the use of integrase inhibitors against HIV-1 subtype C will result in comparable outcomes to those obtained against subtype B infections.This publication has 31 references indexed in Scilit:
- Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistanceRetrovirology, 2009
- Differences in resistance mutations among HIV‐1 non‐subtype B infections: a systematic review of evidence (1996–2008)Journal of the International AIDS Society, 2009
- Analysis of Natural Sequence Variation and Covariation in Human Immunodeficiency Virus Type 1 IntegraseJournal of Virology, 2008
- Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a Series of Drug-Resistant Integrase MutantsBiochemistry, 2008
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionNew England Journal of Medicine, 2008
- Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In VitroAntimicrobial Agents and Chemotherapy, 2008
- Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137)Journal of Virology, 2008
- Integrase and integration: biochemical activities of HIV-1 integraseRetrovirology, 2008
- In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediateRetrovirology, 2007
- Disulfide-Linked Integrase Oligomers Involving C280 Residues Are Formed In Vitro and In Vivo but Are Not Essential for Human Immunodeficiency Virus ReplicationJournal of Virology, 2003